Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
24 hedge funds and large institutions have $91M invested in Alpine Immune Sciences Inc in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 10 closing their positions.
331% more capital invested
Capital invested by funds: $21.1M → $91M (+$69.9M)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
8% less funds holding
Funds holding: 26 → 24 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$30.8M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$20.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$557K |
| 4 |
Renaissance Technologies
New York
|
+$452K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FPF
FNY Partners Fund
New York
|
-$154K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$141K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$81K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$73K |
| 5 |
MML Investors Services
Springfield,
Massachusetts
|
-$48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Northern Trust
Chicago,
Illinois
| – | -$73K | -7,612 | Closed |
|
|
27
MML Investors Services
Springfield,
Massachusetts
| – | -$48K | -5,000 | Closed |
|
|
FPF
28
FNY Partners Fund
New York
| – | -$154K | -4,000 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$14K | -1,445 | Closed |
|
30
Barclays
London,
United Kingdom
| – | -$6K | -675 | Closed |
|
31
Creative Planning
Overland Park,
Kansas
| – | -$6K | -620 | Closed |
|
|
AIM
32
Acrospire Investment Management
Chicago,
Illinois
| – | -$3K | -300 | Closed |
|
33
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -219 | Closed |
|
34
Bank of America
Charlotte,
North Carolina
| – | +$37 | +4 | New |
|
ALPN Hedge Fund Activity: Q3 2017 in Review
24 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q3 2017, worth a combined $91M — up 331% from $21.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ALPN and 9 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 7 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $30.8M. The largest seller was FNY Partners Fund, exiting entirely with an estimated $154K sold.
- 24 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q3 2017, down from 26 in Q2 2017.
- Funds reported $91M of Alpine Immune Sciences Inc stock for Q3 2017, up 331% quarter-over-quarter.
- 9 funds opened new Alpine Immune Sciences Inc positions in Q3 2017 and 10 closed out, a net change of -1 holder.
- The largest Alpine Immune Sciences Inc buyer in Q3 2017 was OrbiMed, an estimated $30.8M added.
- The largest Alpine Immune Sciences Inc seller in Q3 2017 was FNY Partners Fund, an estimated $154K sold.
Based on aggregated 13F filings for Q3 2017.